Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 7/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 3/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2592311 | 0.87 | TSHR (0.62) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL13945620 | 0.86 | TSHR (0.79) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL31636169 | 0.86 | TSHR (0.66) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL30190646 | 0.86 | TSHR (0.66) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL244114 | 0.82 | TSHR (0.95) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL28584786 | 0.81 | TSHR (0.64) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL3416382 | 0.81 | TSHR (0.64) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL8729462 | 0.81 | TSHR (0.64) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL85963 | 0.80 | TSHR (0.75) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL16180095 | 0.80 | TSHR (0.72) | TSHRALDH1A1CYP3A4HPGDTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158748-B2 | Hetero-functional compounds and methods for use thereof | DESIGNER MOLECULES, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-20100041845-A1 | HETERO-FUNCTIONAL COMPOUNDS AND METHODS FOR USE THEREOF | DESIGNER MOLECULES, INC. (US) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041845-A1 | HETERO-FUNCTIONAL COMPOUNDS AND METHODS FOR USE THEREOF | C9, C3AR1, C1S | TSHR 4373/4885ALDH1A1 1455/4885CYP3A4 2077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.